Risk Factors Update Summary

• Proposed spinoff of Renal Care and Acute Therapies may not be completed as announced, subject to customary conditions.
• Select market participants have shown an increased focus on negotiating committed contracts directly with manufacturers.
• The company may not achieve the full efficiencies and cost reduction benefits expected from its initiatives.
• Failure to protect against cyber incidents could lead to substantial regulatory fines, business disruption, and financial loss.
• Incurred $11.80 billion in debt for Hillrom acquisition, impacting financial condition and cash flows.
• The Amended and Restated Bylaws now specify Delaware courts as the exclusive forum for disputes.
• The company divested its BPS business and implemented a simplified operating model.
• The company faces challenges in diversifying sources of components and raw materials, with some sole suppliers.
• Recorded $510 million long-lived asset impairment charges related to HD business in 2023.
• Investors may face increased costs to bring a claim due to the choice of forum provision.
• The company is undertaking actions to simplify its manufacturing footprint and complete the proposed spinoff.
• The company relies on third-party suppliers without contractual arrangements for most components and raw materials.
• The choice of forum provision may limit a stockholder's ability to bring claims in favorable forums.